MX2022009547A - Pemetrexed formulations. - Google Patents

Pemetrexed formulations.

Info

Publication number
MX2022009547A
MX2022009547A MX2022009547A MX2022009547A MX2022009547A MX 2022009547 A MX2022009547 A MX 2022009547A MX 2022009547 A MX2022009547 A MX 2022009547A MX 2022009547 A MX2022009547 A MX 2022009547A MX 2022009547 A MX2022009547 A MX 2022009547A
Authority
MX
Mexico
Prior art keywords
pemetrexed formulations
pemetrexed
formulations
directed
stored
Prior art date
Application number
MX2022009547A
Other languages
Spanish (es)
Inventor
Steven L Krill
Feng-Jing Chen
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2022009547A publication Critical patent/MX2022009547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2°C to 8°C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2°C to 8°C.
MX2022009547A 2016-02-19 2016-02-19 Pemetrexed formulations. MX2022009547A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/018703 WO2017142556A1 (en) 2016-02-19 2016-02-19 Pemetrexed formulations

Publications (1)

Publication Number Publication Date
MX2022009547A true MX2022009547A (en) 2022-09-09

Family

ID=59625349

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010037A MX2018010037A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.
MX2022009547A MX2022009547A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018010037A MX2018010037A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.

Country Status (9)

Country Link
EP (1) EP3416646A4 (en)
JP (1) JP2019505561A (en)
KR (1) KR20180132643A (en)
CN (1) CN109152778B (en)
AU (2) AU2016393213B2 (en)
CA (1) CA3014755C (en)
IL (3) IL301291A (en)
MX (2) MX2018010037A (en)
WO (1) WO2017142556A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
ATE492547T1 (en) * 2006-08-14 2011-01-15 Sicor Inc METHOD FOR PRODUCING LIPOPHILIC PHARMACEUTICALLY ACCEPTABLE SALTS FROM PEMETREXED DISACID
CA2804855A1 (en) * 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
IN2012DE00912A (en) * 2012-03-27 2015-09-11 Fresenius Kabi Oncology Ltd
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
SI2854768T1 (en) * 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Pharmaceutical compositions of pemetrexed
WO2013179310A1 (en) * 2012-05-31 2013-12-05 Mylan Laboratories Limited Stable aqueous compositions of pemetrexed
JP6099557B2 (en) * 2013-12-27 2017-03-22 富士フイルム株式会社 Injection solution preparation and method for producing the same
KR101703980B1 (en) * 2013-12-30 2017-02-08 주식회사 삼양바이오팜 Antioxidant-free pharmaceutical composition and preparation method thereof
EP3206666B1 (en) * 2014-10-16 2019-12-11 Synthon B.V. Liquid pharmaceutical composition comprising pemetrexed

Also Published As

Publication number Publication date
JP2019505561A (en) 2019-02-28
IL290647A (en) 2022-04-01
IL261179A (en) 2018-10-31
IL301291A (en) 2023-05-01
IL261179B (en) 2022-03-01
IL290647B2 (en) 2023-08-01
AU2016393213B2 (en) 2022-03-31
EP3416646A1 (en) 2018-12-26
KR20180132643A (en) 2018-12-12
MX2018010037A (en) 2019-07-04
AU2016393213A1 (en) 2018-10-04
CN109152778A (en) 2019-01-04
IL290647B1 (en) 2023-04-01
CN109152778B (en) 2021-08-10
CA3014755A1 (en) 2017-08-24
WO2017142556A1 (en) 2017-08-24
EP3416646A4 (en) 2019-09-04
CA3014755C (en) 2023-11-14
AU2023202089A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
SI3577110T1 (en) 8-oxetan-3-yl-3,8-diazabicyclo(3.2.1)octan-3-yl substituted compounds as hiv inhibitors
CY1120988T1 (en) MOVEMENT DIAHREL INHIBITORS
BR112017006137A2 (en) formulation containing biotensive
CR20180563A (en) NEW PIPERIDINYL DERIVATIVES REPLACED WITH HETERO (ARILO), A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
MX2019001096A (en) Tlr7/8 antagonists and uses thereof.
EA201691799A1 (en) BICYCLIC COMPOUNDS AS AUTOTAXIN PRODUCT INHIBITORS (ATX) AND LYSOPHOSPHATIDYLIC ACID INHIBITORS (LPA)
EA201691794A1 (en) CONDENSED [1,4] DIAZEPIN COMPOUNDS AS AUTOTAXIN (ATX) PRODUCT INHIBITORS AND LIZOPHOSPHATIDYLIC ACID (LPA) INHIBITORS
BR112017004573A2 (en) detergent compositions containing a branched surfactant
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
EA201591497A1 (en) NEW OXTAGIDROPYRROLO [3,4-C] PYRROL DERIVATIVES AND THEIR ANALOGUES AS AUTOTAXIN INHIBITORS
EA201890858A1 (en) 2,4-DIHYDROXINICOTINAMIDES AS APJ AGONISTS
CL2017000271A1 (en) Optionally condensed heterocyclyl substituted pyrimidine derivatives useful for the treatment of inflammatory, metabolic, oncological and autoimmune diseases
EA201790184A1 (en) PESTICIDAL COMPOSITIONS
EA201791304A1 (en) IZOHINOLINA DERIVATIVES FOR HIV TREATMENT
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
PH12017500839A1 (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
MX2017016619A (en) Pyrimidine derivatives as btk inhibitors and uses thereof.
MX2017002214A (en) Process for the preparation of 5-fluoro-1h-pyrazoles starting from hexafluoropropene.
MX2017008390A (en) Alkoxysilane-functionalized and allophanate-functionalized urethanes.
EP3703692A4 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2016015543A (en) Process for the preparation of 5-fluoro-1h-pyrazoles starting from hexafluoropropene.
EP3694502A4 (en) Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2019010330A (en) Formulations with improved stability.
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2018003903A (en) Bicyclic compound and use thereof for inhibiting suv39h2.